Genetic Mutations Involved in Melanoma: A Summary of Our Current Understanding

Advances in Dermatology

Volumn 23, Issue , 2007, Pages 61-79

  High, Whitney A ^a   Robinson, William A ^b  

^a UNIVERSITY OF COLORADO   (United States)

^b UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; CELL CYCLE PROTEIN; MELANOCORTIN 1 RECEPTOR; MICROPHTHALMIA ASSOCIATED TRANSCRIPTION FACTOR; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PTEN PROTEIN, HUMAN; UNCLASSIFIED DRUG;

ANIMAL; CELL TRANSFORMATION; FAMILIAL CANCER; GENETIC PREDISPOSITION; GENETIC SCREENING; GENETICS; HUMAN; MELANOMA; MUTATION; REVIEW; SKIN TUMOR; TUMOR SUPPRESSOR GENE;

ANIMALS; CELL CYCLE PROTEINS; CELL TRANSFORMATION, NEOPLASTIC; GENES, P16; GENETIC PREDISPOSITION TO DISEASE; GENETIC SCREENING; HUMANS; MELANOMA; MICROPHTHALMIA-ASSOCIATED TRANSCRIPTION FACTOR; MUTATION; NEOPLASTIC SYNDROMES, HEREDITARY; PROTO-ONCOGENE PROTEINS B-RAF; PTEN PHOSPHOHYDROLASE; RECEPTOR, MELANOCORTIN, TYPE 1; SKIN NEOPLASMS;

EID: 36148993957     PISSN: 08820880     EISSN: None     Source Type: Book Series    
DOI: 10.1016/j.yadr.2007.07.009     Document Type: Review

References (134)

1. Rigel D.S., Kopf A.W., and Friedman R.J. The rate of malignant melanoma in the US: are we making an impact?. J Am Acad Dermatol 17 (1987) 1050-1053
2. Jemal A., Siegel R., Ward E., et al. Cancer statistics. CA Cancer J Clin 56 (2006) 106-130
3. Walsh P., Gibbs P., and Gonzalez R. Newer strategies for effective evaluation of primary melanoma and treatment of stage III and IV disease. J Am Acad Dermatol 42 (2000) 480-489
4. Uliasz A., and Lebwohl M. Patient education and regular surveillance results in earlier diagnosis of second primary melanoma. Int J Dermatol 46 (2007) 575-577
5. Garbe C., Buttner P., Weiss J., et al. Risk factors for developing cutaneous melanoma and criteria for identifying persons at risk: multicenter case-control study of the Central Malignant Melanoma Registry of the German Dermatological Society. J Invest Dermatol 102 (1994) 695-699
6. Grob J.J., Gouvernet J., Aymar D., et al. Count of benign melanocytic nevi as a major indicator of risk for nonfamilial nodular and superficial spreading melanoma. Cancer 66 (1990) 387-395
7. Holly E.A., Kelly J.W., Shpall S.N., et al. Number of melanocytic nevi as a major risk factor for malignant melanoma. J Am Acad Dermatol 17 (1987) 459-468
8. Bliss J.M., Ford D., Swerdlow A.J., et al. Risk of cutaneous melanoma associated with pigmentation characteristics and freckling: systematic overview of 10 case-control studies. The International Melanoma Analysis Group (IMAGE). Int J Cancer 62 (1995) 367-376
9. Fountain J.W., Bale S.J., Housman D.E., et al. Genetics of melanoma. Cancer Surv 9 (1990) 645-671
10. Whiteman D.C., Watt P., Purdie D.M., et al. Melanocytic nevi, solar keratoses, and divergent pathways to cutaneous melanoma. J Natl Cancer Inst 95 (2003) 806-812
11. Curtin J.A., Fridlyand J., Kageshita T., et al. Distinct sets of genetic alterations in melanoma. N Engl J Med 353 (2005) 2135-2147
12. Fecher L.A., Cummings S.D., Keefe M.J., et al. Toward a molecular classification of melanoma. J Clin Oncol 25 (2007) 1606-1620
13. Luger T.A., Scholzen T., and Grabbe S. The role of alpha melanocyte stimulating hormone in cutaneous biology. J Investig Dermatol Symp Proc 2 (1997) 87-93
14. Rees J.L. The genetics of sun sensitivity in humans. Am J Hum Genet 75 (2004) 739-751
15. Gantz I., Yamada T., Tashiro T., et al. Mapping of the gene encoding the melanocortin-1 (alpha-melanocyte stimulating hormone) receptor (MC1R) to human chromosome 16q24.3 by Fluorescence in situ hybridization. Genomics 19 (1994) 394-395
16. Cone R.D., Lu D., Koppula S.A., et al. The melanocortin receptors: agonists, antagonists, and the hormonal control of pigmentation. Recent Prog Horm Res 51 (1996) 287-317
17. Valverde P., Healy E., Jackson I., et al. Variants of the melanocyte stimulating hormone receptor gene are associated with red hair and fair skin in humans. Nat Genet 11 (1995) 328-330
18. Smith R., Healy E., Siddiqui S., et al. Melanocortin 1 receptor variants in an Irish population. J Invest Dermatol 111 (1998) 119-122
19. Fox N.F., Wyeth J.R., O'Gorman L.E., et al. Characterization of melanocyte stimulating hormone receptor variants in twins with red hair. Hum Mol Genet 6 (1997) 1891-1897
20. Hunt G., Todd C., and Thody A.J. Unresponsiveness of human epidermal melanocytes to melanocyte-stimulating hormone and its association with red hair. Mol Cell Endocrinol 116 (1996) 131-136
21. Frandberg P.A., Doufexis M., Kapas S., et al. Human pigmentation phenotype: a point mutation generates nonfunctional MSH receptor. Biochem Biophys Res Commun 245 (1998) 490-492
22. Healy E., Flannagan N., Ray A., et al. Melanocortin-1-receptor gene and sun sensitivity in individuals without red hair. Lancet 355 (2000) 1072-1073
23. Valverde P., Healy E., Sikkink S., et al. The Asp84Glu variant of the melanocortin 1 receptor is associated with melanoma. Hum Mol Genet 5 (1996) 1663-1666
24. Gruis N.A., van der Velden P.A., Sandkuijl L.A., et al. Variants of the melanocyte-stimulating hormone receptor gene modify melanoma risk in familial atypical multiple mole-melanoma (FAMM) syndrome families. [abstract]. Melanoma Res 7 (1997) S9
25. Palmer J.S., Duffy D.L., Box N.F., et al. Melanocortin-1 receptor polymorphisms and risk of melanoma: is the association explained solely by pigmentation phenotype?. Am J Hum Genet 66 (2000) 176-186
26. Wong T.H., and Rees J.L. The relation between melanocortin 1 receptor (MC1R) variation and the generation of phenotypic diversity in the cutaneous response to ultraviolet radiation. Peptides 26 (2005) 1965-1971
27. Galore G., Azizi E., Scope A., et al. The Y152X MC1R gene mutation: occurrence in ethnically diverse Jewish malignant melanoma patients. Melanoma Res 17 (2007) 105-108
28. Box N.F., Duffy D.L., Chen W., et al. MC1R genotype modifies risk of melanoma in families segregating CDKN2A mutations. Am J Hum Genet 69 (2001) 765-773
29. Pho L., Grossman D., and Leachman S.A. Melanoma genetics: a review of genetic factors and clinical phenotypes in familial melanoma. Curr Opin Oncol 18 (2006) 173-179
30. Norbury C., and Nurse P. Animal cell cycles and their control. Annu Rev Biochem 61 (1992) 441-470
31. Cannon-Albright L.A., Goldgar D.E., Meyer L.J., et al. Assignment of a locus for familial melanoma, MLM, to chromosome 9p13-22. Science 258 (1992) 1148-1152
32. Ortega S., Malumbres M., and Barbacid M. Cyclin D-dependent kinases, INK4 inhibitors and cancer. Biochim Biophys Acta 1602 (2002) 73-87
33. Zhu L. Tumour suppressor retinoblastoma protein Rb: a transcriptional regulator. Eur J Cancer 41 (2005) 2415-2427
34. Serrano M., Lee H., Chin L., et al. Role of the INK4a locus in tumor suppression and cell mortality. Cell 85 (1996) 27-37
35. Chin L., Pomerantz J., Polsky D., et al. Cooperative effects of INK4A and ras in melanoma susceptibility in vivo. Genes Dev 11 (1997) 2822-2834
36. Kefford R., Bishop J.N., Tucker M., et al. Genetic testing for melanoma. Lancet Oncol 3 (2002) 653-654
37. Rizos H., Darmanian A.P., Holland E.A., et al. Mutations in the INK4A/ARF melanoma susceptibility locus functionally impair p14ARF. J Biol Chem 276 (2001) 41424-41434
38. Rizos H., Puig S., Badenas C., et al. A melanoma-associated germline mutation in exon 1beta inactivates p14ARF. Oncogene 20 (2001) 5543-5547
39. Hussussian C.J., Streuewig J.P., Goldstein A.M., et al. Germline p16 mutations in familial melanoma. Nat Genet 8 (1994) 15-21
40. Cannon-Albright L.A., Meyer L.J., Goldgar D.E., et al. Penetrance and expressivity of the chromosome 9p melanoma susceptibility locus (MLM). Cancer Res 54 (1994) 6041-6044
41. Walker G.J., Hussussian C.J., Flores J.F., et al. Mutations of the CDKN2/p16INK4 gene in Australian melanoma kindreds. Hum Mol Genet 4 (1995) 1845-1852
42. Foulkes W.D., Flanders T.Y., Pollock P.M., et al. The CDKN2A (p16) gene and human cancer. Mol Med 3 (1997) 5-20
43. Liggett Jr. W.H., and Sidransky D. Role of the p16 tumor suppressor gene in cancer. J Clin Oncol 16 (1998) 1197-1206
44. Peng H.Q., Bailey D., Bronson D., et al. Loss of heterozygosity of tumor suppressor genes in testis cancer. Cancer Res 55 (1995) 2871-2875
45. Funk JO, Schiller PI, Barrett MT, et al. p16INK4a expression is frequently decreased and associated with 9p21 loss of heterozygosity in sporadic melanoma. J Cutan Pathol 2998; 25:291-6.
46. Flores J.F., Walker G.H., Glendening J.M., et al. Loss of the p16INK4a and p15INK4b genes as well as neighboring 9p21 markers, in sporadic melanoma. Cancer Res 56 (1996) 5023-5032
47. van der Velden P.A., Metzelaar-Blok J.A., Bergman W., et al. Promoter hypermethylation: a common cause of reduced p16(INK4a) expression in uveal melanoma. Cancer Res 61 (2001) 5303-5306
48. Fujimoto A., Morita R., Hatta N., et al. p16INK4a inactivation is not frequent in uncultured sporadic primary cutaneous melanoma. Oncogene 18 (1999) 2527-2532
49. Gruis N.A., Weaver-Feldhaus J., Liu Q., et al. Genetic evidence in melanoma and bladder cancers that p16 and p53 function in separate pathways of tumor suppression. Am J Pathol 146 (1995) 1199-1206
50. Aitken J., Welch J., Duffy D., et al. CDKN2A variants in a population-based sample of Queensland families with melanoma. J Natl Cancer Inst 91 (1999) 446-452
51. Kumar R., Lundh Rozell B., Louhelainen J., et al. Mutations in the CDKN2A (p16INK4a) gene in microdissected sporadic primary melanomas. Int J Cancer 75 (1998) 193-198
52. Reed J.A., Loganzo F., Shea C.R., et al. Loss of expression of the p16/cyclin-dependent kinase inhibitor 2 tumor suppressor gene in melanocytic lesions correlates with invasive stage of tumor progression. Cancer Res 55 (1995) 2713-2718
53. Sparrow L.E., Eldon M.J., English D.R., et al. p16 and p21WAF1 protein expression in melanocytic tumors by immunohistochemistry. Am J Dermatopathol 20 (1998) 255-261
54. Keller-Melchior R., Schmidt R., and Piepkorn M. Expression of the tumor suppressor gene product p16INK4 in benign and malignant melanocytic lesions. J Invest Dermatol 110 (1998) 932-938
55. Talve L., Sauroja I., Collan Y., et al. Loss of expression of the p16INK4/CDKN2 gene in cutaneous malignant melanoma correlates with tumor cell proliferation and invasive stage. Int J Cancer 74 (1997) 255-259
56. Straume O., and Akslen L.A. Alterations and prognostic significance of p16 and p53 protein expression in subgroups of cutaneous melanoma. Int J Cancer 74 (1997) 535-539
57. Winnepenninckx V., and van den Oord J.J. p16INK4A expression in malignant melanomas with or without a contiguous naevus remnant: a clue to their divergent pathogenesis?. Melanoma Res 14 (2004) 321-322
58. Pavey S.J., Cummings M.C., Whiteman D.C., et al. Loss of p16 expression is associated with histological features of melanoma invasion. Melanoma Res 12 (2002) 539-547
59. Li W., Sanki A., Karim R.Z., et al. The role of cell cycle regulatory proteins in the pathogenesis of melanoma. Pathology 38 (2006) 287-301
60. Miller A.J., and Mihm M.C. Mechanisms of disease: melanoma. N Engl J Med 355 (2006) 51-65
61. Soufir N., Avril M.F., Chompret A., et al. Prevalence of p16 and CDK4 germline mutations in 48 melanoma-prone families in France. The French Familial Melanoma Study Group. Hum Mol Genet 7 (1998) 209-216
62. Zuo L., Weger J., Yang Q., et al. Germline mutations in the p16INK4a binding domain of CDK4 in familial melanoma. Nat Genet 12 (1996) 97-99
63. Sotillo R., Garcia J.F., Ortega S., et al. Invasive melanoma in CDK4-targeted mice. Proc Natl Acad Sci U S A 98 (2001) 13312-13317
64. Muthusamy V., Hobbs C., Nogueira C., et al. Amplification of CDK4 and MDM2 in malignant melanoma. Genes Chromosomes Cancer 45 (2006) 447-454
65. Sauter E.R., Yeo U.C., von Stemm A., et al. Cyclin D1 is a candidate oncogene in cutaneous melanoma. Cancer Res 62 (2002) 3200-3206
66. Bastian B.C., Kashani-Sabet M., Hamm H., et al. Gene amplifications characterize acral melanoma and permit the detection of occult tumor cells in the surrounding skin. Cancer Res 60 (2000) 1668-1673
67. Errico M.E., Staibano S., Tranfa A., et al. Expression of cyclin-D1 in uveal malignant melanoma. Anticancer Res 23 (2003) 2701-2706
68. Coupland S.E., Anastassiou G., Stang A., et al. The prognostic value of cyclin D1, p53, and MDM2 protein expression in uveal melanoma. J Pathol 191 (2000) 120-126
69. Florenes V.A., Faye R.S., Maelandsmo G.M., et al. Levels of cyclin D1 and D3 in malignant melanoma: deregulated cyclin D3 expression is associated with poor clinical outcome in superficial melanoma. Clin Cancer Res 6 (2000) 3614-3620
70. Bachmann I.M., Straume O., and Akslen L.A. Altered expression of cell cycle regulators cyclin D1, p14, p16, CDK4 and Rb in nodular melanomas. Int J Oncol 25 (2004) 1559-1565
71. Alonso S.R., Ortiz P., Pollan M., et al. Progression in cutaneous malignant melanoma is associated with distinct expression profiles: a tissue microarray-based study. Am J Pathol 164 (2004) 193-203
72. Sharpless E., and Chin L. The INK4a/ARF locus and melanoma. Oncogene 22 (2003) 3092-3098
73. Packer L.M., Pavey S.J., Boyle G.M., et al. Gene expression profiling in melanoma identifies novel downstream effectors of p14ARF. Int J Cancer 121 (2007) 784-790
74. Kamijo T., Bodner S., van de Kamp E., et al. Tumor spectrum in ARF-deficient mice. Cancer Res 59 (1999) 2217-2222
75. Sharpless N.E., Bardeesy N., Lee K.H., et al. Loss of p16Ink4a with retention of p19Arf predisposes mice to tumorigenesis. Nature 413 (2001) 86-91
76. Kannan K., Sharpless N.E., Xu J., et al. Components of the Rb pathway are critical targets of UV mutagenesis in a murine melanoma model. Proc Natl Acad Sci U S A 100 (2003) 1221-1225
77. Sarkar-Agrawal P., Vergilis I., Sharpless N.E., et al. Impaired processing of DNA photoproducts and ultraviolet hypermutability with loss of p16INK4a or p19ARF. 1. J Natl Cancer Inst 96 (2004) 1790-1793
78. Davies H., Bignell G.R., Cox C., et al. Mutations of the BRAF gene in human cancer. Nature 417 (2002) 949-954
79. Brose M.S., Volpe P., Feldman M., et al. BRAF and RAS mutations in human lung cancer and melanoma. Cancer Res 62 (2002) 6997-7000
80. Wellbrock C., Ogilvie L., Hedley D., et al. V599EB-RAF is an oncogene in melanocytes. Cancer Res 64 (2004) 2338-2342
81. Hingorani S.R., Jacobetz M.A., Robertson G.P., et al. Suppression of BRAF (V599E) in human melanoma abrogates transformation. Cancer Res 63 (2003) 5198-5202
82. Pollock P.M., Harper U.L., Hansen K.S., et al. High frequency of BRAF mutations in nevi. Nat Genet 33 (2003) 19-20
83. Meyer P., Sergi C., and Garbe C. Polymorphisms of the BRAF gene predispose males to malignant melanoma. J Carcinog 2 (2003) 7
84. Jackson S., Harland M., Turner F., et al. No evidence for BRAF as a melanoma/nevus susceptibility gene. Cancer Epidemiol Biomarkers Prev 14 (2005) 913-918
85. Yazdi A.S., Palmedo G., Flaig M.J., et al. Mutations of the BRAF gene in benign and malignant melanocytic lesions. J Invest Dermatol 121 (2003) 1160-1162
86. van Dijk M.C., Bernsen M.R., and Ruiter D.J. Analysis of mutations in B-RAF, N-RAS, and H-RAS genes in the differential diagnosis of Spitz nevus and Spitzoid melanoma. Am J Surg Pathol 29 (2005) 1145-1151
87. Gill M., Cohen J., Renwick N., et al. Genetic similarities between Spitz nevus and Spitzoid melanoma in children. Cancer 101 (2004) 2636-2640
88. Saldanha G., Purnell D., Fletcher A., et al. High BRAF mutation frequency does not characterize all melanocytic tumor types. Int J Cancer 111 (2004) 705-710
89. Mihic-Probst D., Perren A., Schmid S., et al. Absence of BRAF gene mutations differentiates Spitz nevi from malignant melanoma. Anticancer Res 24 (2004) 2415-2418
90. Palmedo G., Hantschke M., Rütten A., et al. The T1796A mutation of the BRAF gene is absent in Spitz nevi. J Cutan Pathol 31 (2004) 266-270
91. Gill M., Renwick N., Silvers D.N., et al. Lack of BRAF mutations in Spitz nevi. J Invest Dermatol 122 (2004) 1325-1326
92. Turner D.J., Zirvi M.A., Barany F., et al. Detection of the BRAF V600E mutation in melanocytic lesions using the ligase detection reaction. J Cutan Pathol 32 (2005) 334-339
93. Barnhill R.L., Argenyi Z.B., From L., et al. Atypical Spitz nevi/tumors: lack of consensus for diagnosis, discrimination from melanoma, and prediction of outcome. Hum Pathol 30 (1999) 513-520
94. Ruiter D.J., van Dijk M.C., and Ferrier C.M. Current diagnostic problems in melanoma pathology. Semin Cutan Med Surg 22 (2003) 33-41
95. LeBoit P.E. 'Safe' Spitz and its alternatives. Pediatr Dermatol 19 (2002) 163-165
96. Urso C. A new perspective for Spitz tumors?. Am J Dermatopathol 27 (2005) 364-366
97. Cerroni L. A new perspective for Spitz tumors?. Am J Dermatopathol 27 (2005) 366-367
98. Mones J.M., and Ackerman A.B. Atypical Spitz's nevus, "malignant" Spitz's nevus, and "metastasizing" Spitz's nevus: a critique in historical perspective of three concepts flawed fatally. Am J Dermatopathol 26 (2004) 310-333
99. Fullen D.R., Poynter J.N., Lowe L., et al. BRAF and NRAS mutations in spitzoid melanocytic lesions. Mod Pathol 19 (2006) 1324-1332
100. Takata M., Lin J., Takayanagi S., et al. Genetic and epigenetic alterations in the differential diagnosis of malignant melanoma and spitzoid lesion. Br J Dermatol 156 (2007) 1287-1294
101. Liaw D., Marsh D.J., Li J., et al. Germline mutations of the PTEN gene in Cowden disease, an inherited breast and thyroid cancer syndrome. Nat Genet 16 (1997) 64-67
102. Arch E.M., Goodman B.K., Van Wesep R.A., et al. Deletion of PTEN in a patient with Bannayan-Riley-Ruvalcaba syndrome suggests allelism with Cowden disease. 1. Am J Med Genet 71 (1997) 489-493
103. Cantley L.C., and Neel B.G. New insights into tumor suppression: PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase/AKT pathway. Proc Natl Acad Sci U S A 96 (1999) 4240-4245
104. Wu H., Goel V., and Haluska F.G. PTEN signaling pathways in melanoma. Oncogene 22 (2003) 3113-3122
105. Gomez-Gutierrez J.G., Souza V., Hao H.Y., et al. Adenovirus-mediated gene transfer of FKHRL1 triple mutant efficiently induces apoptosis in melanoma cells. Cancer Biol Ther 5 (2006) 875-883
106. Stahl J.M., Cheung M., Sharma A., et al. Loss of PTEN promotes tumor development in malignant melanoma. Cancer Res 63 (2003) 2881-2890
107. Stahl J.M., Sharma A., Cheung M., et al. Deregulated Akt3 activity promotes development of malignant melanoma. Cancer Res 64 (2004) 7002-7010
108. Widlund H.R., and Fisher D.E. Microphthalmia-associated transcription factor: a critical regulator of pigment cell development and survival. Oncogene 22 (2003) 3035-3041
109. Levy C., Khaled M., and Fisher D.E. MITF: master regulator of melanocyte development and melanoma oncogene. Trends Mol Med 12 (2006) 406-414
110. Garraway L.A., Widlund H.R., Rubin M.A., et al. Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma. Nature 436 (2005) 117-122
111. McGill G.G., Horstmann M., Widlund H.R., et al. BCL2 regulation by the melanocyte master regulator MITF modulates lineage survival and melanoma cell viability. Cell 109 (2002) 707-718
112. Loercher A.E., Tank E.M., Delston R.B., et al. MITF links differentiation with cell cycle arrest in melanocytes by transcriptional activation of INK4A. J Cell Biol 168 (2005) 35-40
113. Du J., Miller A.J., Widlund H.R., et al. MLANA/MART1 and SILV/PMEL17/GP100 are transcriptionally regulated by MITF in melanocytes and melanoma. Am J Pathol 163 (2003) 333-343
114. Miller A.J., Du J., Rowan S., et al. Transcriptional regulation of the melanoma prognostic marker melastatin (TRPM1) by MITF in melanocytes and melanoma. Cancer Res 64 (2004) 509-516
115. Hofbauer G.F., Kamarashev J., Geertsen R., et al. Melan A/MART-1 immunoreactivity in formalin-fixed paraffin-embedded primary and metastatic melanoma: frequency and distribution. Melanoma Res 8 (1998) 337-343
116. Salti G.I., Manougian T., Farolan M., et al. Microphthalmia transcription factor: a new prognostic marker in intermediate-thickness cutaneous malignant melanoma. Cancer Res 60 (2000) 5012-5016
117. Seiter S., Monsurro V., Nielsen M.B., et al. Frequency of MART-1/MelanA and gp100/PMel17-specific T cells in tumor metastases and cultured tumor-infiltrating lymphocytes. J Immunother 25 (2002) 252-263
118. Takeuchi H., Kuo C., Morton D.L., et al. Expression of differentiation melanoma-associated antigen genes is associated with favorable disease outcome in advanced-stage melanomas. Cancer Res 63 (2003) 441-448
119. Landi M.R., Bauer J., Pfeiffer R.M., et al. MC1R germline variants confer risk for BRAF-mutant melanoma. Science 313 (2006) 521-522
120. Carli P., DeGiorgi V., Palli D., et al. Dermatologist detection and skin self-examination are associated with thinner melanomas: results from a survey on the Italian Multidisciplinary Group on Melanoma. Arch Dermatol 139 (2003) 607-612
121. Koh H.K., Norton L.A., Geller A.C., et al. Evaluation of the American Academy of Dermatologys National Skin Cancer Early Detection and Screening Program. J Am Acad Dermatol 34 (1996) 971-978
122. Masri G.D., Clark Jr. W.H., Guerry D., et al. Screening and surveillance of patients at high risk for malignant melanoma result in detection of earlier disease. J Am Acad Dermatol 22 (1990) 1042-1048
123. University of Washington. Gene Tests (webpage). Laboratories offering genetic testing for familial malignant melanoma. Available at: http://www.genetests.org/servlet/access?prg=j&;db=genetests&site =gt&id=8888891&fcn=c&qry=2109&res=nous&res=nointl &key=01h6O-HSLSvWo&show_flag=c. Accessed July 1, 2007.
124. Kefford R.F., Newton Bishop J.A., Bergman W., et al. Counseling and DNA testing for individuals perceived to be genetically predisposed to melanoma: a consensus statement of the Melanoma Genetic Consortium. J Clin Oncol 17 (1999) 3245-3251
125. Hansen C.B., Wadge L.M., Lowstuter K., et al. Clinical germline genetic testing for melanoma. Lancet Oncol 5 (2004) 314-319
126. Niendorf K.B., and Tsao H. Cutaneous melanoma: family screening and genetic testing. Dermatol Ther 19 (2006) 1-8
127. Kasparian N.A., Meiser B., Butow P.N., et al. Better the devil you know? High-risk individuals' anticipated psychological responses to genetic testing for melanoma susceptibility. J Genet Couns 15 (2006) 433-447
128. Kasparian N.A., Butow P.N., Meiser B., et al. High- and average-risk individuals' beliefs about, and perceptions of, malignant melanoma: an Australian perspective. Psychooncology (2007) [Epub ahead of print]
129. Tsai J., Zhang J., Bremer R., et al. Development of a novel inhibitor of cogenic BRAF. AACR Meeting. Proc Am Assoc Cancer Res 47 (2006) 571a [abstract 2412]
130. Schwarz G.K., and Shah M.A. Targeting the cell cycle: a new approach to cancer therapy. J Clin Oncol 23 (2005) 9408-9421
131. Sausville E.A., Arbuck S.G., Messmann R., et al. Phase I trial of 72-hour continuous infusion UCN-01 in patients with refractory neoplasms. J Clin Oncol 19 (2001) 2319-2333
132. Granville C.A., Memmott R.M., Gills J.J., et al. Handicapping the race to develop inhibitors of the phosphoinositide 3-kinase/Akt/mammalian target of rapamycin pathway. Clin Cancer Res 12 (2006) 679-689
133. Margolin K., Longmate J., Baratta T., et al. CCI-779 in metastatic melanoma: a phase II trial of the California Cancer Consortium. Cancer 104 (2005) 1045-1048
134. Rao R.D., Widschitl H.E., Allred J.B., et al. Phase II trial of the mTOR inhibitor everolimus (RAD-001) in metastatic melanoma. J Clin Oncol 24 (2006) 18s [abstract 8043]